Thorenco’s vision is to become the world leader in the production of alpha-emitting medical isotopes and is committed to delivering secure and sustainable quantities of these important isotopes to global healthcare markets.  The Company plans to initially produce actinium-227 to supply the needs of the medical research community and the global market needs of the commercial healthcare/pharmaceutical sector.

Actinium-227 is a valuable isotope – it is the parent isotope of two emerging alpha-emitting medical isotopes with important applications. One, radium-223, is useful for the treatment of cancers that have spread to bone. The second, thorium-227 is being studied for targeted alpha therapies to treat certain types of primary cancer tumors.

Alpha particles have a very short range (4/1000th inch) and when properly delivered to cancer cells the particles do not damage out of range healthy cells. Unwanted side effects can be reduced when alpha particles are targeted.

Thorenco Medical Isotopes LLC looks forward to establishing enduring relationships with researchers, firms and institutions advancing this important field.